BackMEDIROM Healthcare Technologies Overview

MEDIROM Healthcare Technologies Profit Margin

Valuation check: MRM's profit margin is 2.32%, below the Consumer Discretionary sector average of 9.32%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

10.36%
31.60% YoY

As of Dec 2025

Annual Profit Margin (TTM)

2.32%
59.61% YoY

Trailing 12 months ending Dec 2025

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

MEDIROM Healthcare Technologies (MRM) FAQ

The latest profit margin for MRM is 2.32% as of December 2025. That compares with 1.46% in the prior-year period — up 59.6% year over year. That is below the Consumer Discretionary sector average of 9.32%. Investors often review this figure alongside MEDIROM Healthcare Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRM's profit margin moved from 1.46% to 2.32% — a 59.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MEDIROM Healthcare Technologies's valuation or profitability profile.

Against Consumer Discretionary companies, MRM currently prints 2.32% for profit margin, while the sector average sits near 9.32%. That is roughly 75.1% below the sector mean. Large gaps often invite a closer look at MEDIROM Healthcare Technologies's growth, margins, and balance sheet.

Profit Margin shows how effectively MEDIROM Healthcare Technologies converts resources into returns. At 2.32%, MRM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 1.46% in the prior-year period — up 59.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MRM's profit margin (2.32%), review year-over-year change from 1.46%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.